The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart. Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.

Start Date01 Oct 2008

Sponsor / Collaborator

Molecular Targeting Technologies, Inc.

[+5]

100 Clinical Results associated with 99m Tc-glucarate(Molecular Targeting Technologies, Inc.)

100 Translational Medicine associated with 99m Tc-glucarate(Molecular Targeting Technologies, Inc.)

100 Patents (Medical) associated with 99m Tc-glucarate(Molecular Targeting Technologies, Inc.)

Literatures (Medical) associated with 99m Tc-glucarate(Molecular Targeting Technologies, Inc.)

01 Apr 2012·World Journal of Nuclear Medicine

99m Tc glucarate as a potential radiopharmaceutical agent for assessment of tumor viability: From bench to the bed side

Article

Author: Dondi, M. ; Gambini, J. ; Gupta, A. ; Savio, E. ; Solanki, K. ; Alonso, O. ; Doval, Dinesh ; Choudhury, Partha ; Sharma, P.

Several radiotracers have been used for assessing cell death, whether by necrosis or apoptosis. 99m Tc glucarate, which has initially been reported to be concentrating/accumulating in myocardial infarction or zones of cerebral injury, has also shown some tumor-seeking properties in a few preliminary studies. Under International Atomic Energy Agency (IAEA)′s coordinated research program, we report here the standardization, quality control, and clinical evaluation (detection, evaluation of response, and comparison with 18 F Fluorodeoxyglucose) of this tracer in well-characterized lung cancer and head neck malignancies in a single-arm prospective observational study. Forty-seven patients (29 inoperable lung carcinoma and 18 head and neck malignancies) were prospectively enrolled and underwent 99m Tc glucarate imaging [whole body planar and single-photon emission computed tomography of the region of interest] 4-5 hours after injection of 20 mCi of the radiopharmaceutical. Excellent 99m Tc glucarate concentration was noted in the target lesion in lung cancer and head and neck malignancies. The sensitivity was found to be better in lung cancer. Avid concentration of tracer was seen in the metastatic sites. During response evaluation, the glucarate concentration correlated well with the clinical and other radiological findings. 99m Tc glucarate showed avid concentration of tracer in the tumor, suggesting it to be a potential tumor imaging agent which can be used for detection and assessment of therapeutic response in malignancy.

01 Feb 2011·Nuclear Medicine and BiologyQ4 · MEDICINE

Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model

Q4 · MEDICINE

Article

Author: Figueroa, Said Daibes ; Zhang, Xiuli ; Ma, Lixin ; Deutscher, Susan L. ; Cabral, Pablo ; Alonso, Omar ; Quinn, Thomas P. ; Savio, Eduardo ; Gambini, Juan Pablo

INTRODUCTIONThe use of [(99m)Tc]glucarate has been reported as an infarct-avid agent with the potential for very early detection of myocardial infarction. [(99m)Tc]Glucarate has also been postulated as an agent for non-invasive detection of tumors. The aim of our study was to develop a Glucarate kit and evaluate [(99m)Tc]glucarate as a potential cancer imaging agent in female SCID mice bearing human MDA-MB-435 breast tumors.METHODSGlucarate in a kit formulation was labeled with (99m)Tc and evaluated for radiolabelling efficiency and radiochemical purity. The Glucarate kit stability was assessed by monthly quality controls. The pharmacokinetics of [(99m)Tc]glucarate were determined in female SCID mice bearing MDA-MB-435 human breast carcinoma tumors at 0.5, 1, 2, 4 and 24 h. Nuclear imaging studies were performed with a micro-single photon emission tomography (SPECT)/computed tomography (CT) system at 2 h post injection, while magnetic resonance imaging (MRI) was employed for tumor morphology analysis and metastatic deposit localization.RESULTSThe Glucarate kits exhibited a stable shelf life of 6 months. [(99m)Tc]Glucarate was obtained with radiochemical purity greater than 95%. Biodistribution studies demonstrated moderate tumor uptake coupled with high renal clearance. Tumor-to-muscle ratios were 4.85 and 5.14 at 1 and 4 h post injection. MRI analysis showed tumors with dense cellular growth and moderate central necrosis. [(99m)Tc]Glucarate uptake in the primary MDA-MB-435 shoulder tumors and metastatic lesions were clearly visualized with micro-SPECT/CT imaging.CONCLUSIONSSelective tumor uptake and rapid clearance from nontarget organs makes [(99m)Tc]glucarate a potential agent for breast cancer imaging that awaits validation in a clinical trial.

01 Oct 2010·European Journal of Nuclear Medicine and Molecular ImagingQ1 · MEDICINE

99mTc-glucarate kinetics differentiate normal, stunned, hibernating, and nonviable myocardium in a perfused rat heart model

Q1 · MEDICINE

Article

Author: Liu, Zhonglin ; Okada, Robert D. ; Beju, Delia ; Khaw, Ban An ; Okada, David R. ; Johnson, Gerald III

PURPOSE(99m)Tc-glucarate is an infarct-avid imaging agent. However, patients may have mixtures of normal, irreversibly injured, stunned, and hibernating myocardium. The purposes were to determine (99m)Tc-glucarate uptake and clearance kinetics in these four conditions, and its ability to determine the extent of injury.METHODSTwenty-two perfused rat hearts were studied: controls (n = 5), stunned (n = 5; 20-min no-flow followed by 5-min reflow), hibernating (n = 6; 120-min low flow at 4 ml/min), and ischemic-reperfused (n = 6; 120-min no-flow followed by reflow). (99m)Tc-glucarate was then infused. Tracer activity was monitored using a NaI scintillation detector and a multichannel analyzer. Creatine kinase, electron microscopy, and triphenyltetrazolium chloride determined viability.RESULTS(99m)Tc-glucarate 10-min myocardial uptake was significantly greater in ischemic-reperfused (2.50 +/- 0.09) (cpm, SEM) than in control (1.74 +/- 0.07), stunned (1.68 +/- 0.11), and hibernating (1.59 +/- 0.11) (p < 0.05). Tracer retention curves for ischemic-reperfused were elevated at all time points as compared with the other groups. (99m)Tc-glucarate 60-min myocardial uptake was significantly greater in ischemic-reperfused (7.60 +/- 0.63) than in control (1.98 +/- 0.15), stunned (1.79 +/- 0.08), and hibernating (2.33 +/- 0.15) (p < 0.05). The 60-min well-counted tracer activity ratio of ischemic-reperfused to control was 9:1 and corroborated the NaI detector results. Creatine kinase, triphenyltetrazolium chloride, and electron microscopy all demonstrated significantly greater injury in ischemic-reperfused compared to the other groups. An excellent correlation was observed between viability markers and tracer activity (r = 0.99 triphenyltetrazolium chloride; r = 0.90 creatine kinase).CONCLUSION(99m)Tc-glucarate activity continually and progressively increased in irreversibly injured myocardium. (99m)Tc-glucarate uptake was strongly correlated with myocardial necrosis as determined by three independent assessments of viability. There were minimal and similar (99m)Tc-glucarate uptakes in control, stunned, and hibernating myocardium.

100 Deals associated with 99m Tc-glucarate(Molecular Targeting Technologies, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Injuries	Phase 3	DE	Molecular Targeting Technologies, Inc.	27 Sep 2022
Neoplasms	Phase 3	DE	Molecular Targeting Technologies, Inc.	27 Sep 2022
Acrocallosal Syndrome	Discovery	US	Molecular Targeting Technologies, Inc.	01 Oct 2008
Acute Coronary Syndrome	Discovery	US	Molecular Targeting Technologies, Inc.	01 Oct 2008
Acute myocardial infarction	Discovery	US	Molecular Targeting Technologies, Inc.	01 Oct 2008
Chest Pain	Discovery	US	Molecular Targeting Technologies, Inc.	01 Oct 2008
Coronary Artery Disease	Discovery	US	Molecular Targeting Technologies, Inc.	01 Oct 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2014	Not Applicable	Non-Small Cell Lung Cancer	-	99mTc-glucarate (H292 lung adenocarcinoma cell line)	xbkwiorati(uaaxsryaln) = pfnvtvtgkm bccreqosze (harqmqashd ) View more	-	05 Nov 2014
				99mTc-glucarate (A549 lung adenocarcinoma cell line)	xbkwiorati(uaaxsryaln) = tqxabnxlrq bccreqosze (harqmqashd ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

99m Tc-glucarate(Molecular Targeting Technologies, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation